Metabolic disease

Molecular therapy for body weight control, energy homeostasis and TIIDM: Aleglitazar, a PPARα and PPARγ agonist, inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 7/June/2019, 11.30 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: Aleglitazar, a PPARα and PPARγ agonist, inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 7/June/2019, 11.30 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Mechanistic insights into how Liraglutide aids in control of body weight, energy homeostasis and TIIDM: Liraglutide (brand name: Victoza, Saxenda and others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/May/2019, 12.27 am
Mechanistic insights into how Liraglutide aids in control of body weight, energy homeostasis and TIIDM: Liraglutide (brand name: Victoza, Saxenda and others), a  drug used in the treatment of type II diabetes, increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 4/May/2019, 12.27 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Sugar-based learning/memory/cognitive-enhancement therapy:Raffinose, a trisaccharide composed of galactose, glucose, and fructose,  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down regulation of its target genes, 31/March/2018, 11.30 pm
Sugar-based learning/memory/cognitive-enhancement therapy:Raffinose, a trisaccharide composed of galactose, glucose, and fructose,  increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down regulation of its target genes, 31/March/2018, 11.30 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA;  Paul F. Glenn Center for the Biology of…

read more

Hydrogen gas-based therapy for TIIDM and obesity-associated metabolic deficits: Hydrogen gas therapy increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 28/March/2018, 10.57 am
Hydrogen gas-based therapy for TIIDM and obesity-associated metabolic deficits: Hydrogen gas therapy increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 28/March/2018, 10.57 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors  BigH3 and TIPE2, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 21/March/2018, 9.36 am
Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors  BigH3 and TIPE2, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 21/March/2018, 9.36 am 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors TPM1 and TAp63, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 14/March/2017, 10.43 pm
Sugar-based therapy for Metastatic cancers: Xylobiose, a disaccharide of xylose, increases the expression of tumor/metastatic suppressors TPM1 and TAp63, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 14/March/2017, 10.43 pm 960 720 Dr Boomi's Genom-2-Discovery Center

From Significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more
Start Typing